High density atrial fibrillation cycle length (AFCL) detection and mapping system

a high density atrial fibrillation and detection and mapping technology, applied in the field of intervention and treatment of heart conditions, can solve the problems of embolic stroke, limited ablating focal triggers, and heart stopping blood pumping,

Inactive Publication Date: 2005-12-29
BOSTON SCI SCIMED INC
View PDF8 Cites 111 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] The invention concerns the automated determination of atrial fibrillation cycle length values and the manipulation and derivation of further parameters and statistics therefrom. Electrocardiogram signals can be annotated using this information and one or more maps can be created which coordinate location information of indwelling catheter electrodes with AFCL data and its derivatives. Ablation therapy can proceed under guidance of such maps.

Problems solved by technology

This inevitably results in that part of the heart ceasing to pump blood, which in turn can lead to embolic stroke.
Though mapping and ablation of these triggers appears to be curative in most patients with paroxysmal AF, there are a number of limitations to ablating focal triggers via mapping and ablating the earliest site of activation with a “point” radiofrequency lesion.
However, there is still recurrence of atrial fibrillation after catheter ablation.
It is difficult to predict the long-term success or recurrence.
However, the mechanism of this kind of approach is not clear and may in fact be destructive to mechanical function of the heart in the long term.
However, due to the chaotic nature of waveforms during AF, it is difficult to interpret cycle length of atrial tissue on a beat-by-beat basis.
The procedure is subjective, tedious and is time-consuming and has not provided a convenient, rapid, and repeatable approach to evaluating and utilizing AFCL determinations.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • High density atrial fibrillation cycle length (AFCL) detection and mapping system
  • High density atrial fibrillation cycle length (AFCL) detection and mapping system
  • High density atrial fibrillation cycle length (AFCL) detection and mapping system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] By way of overview and introduction, when heart cells are activated, the electrical polarization caused by the normal voltage difference of about 90 mV between the inside and outside of the cells collapses and the heart tissue is said to “depolarize.” Depolarized heart tissue which has not been given adequate time to re-establish its normal voltage difference and will not produce a new activation in response to a further intrinsic or extrinsic electrical stimulus is referred to as refractory tissue. After depolarization, heart cells begin to re-establish the normal voltage difference (“repolarization”). Tissue which has been afforded an adequate length of time to re-establish a sufficiently large voltage difference to once again become susceptible to depolarization is no longer refractory. The time interval which is required after a cell has been depolarized until it is again non-refractory is called the refractory period. In a fibrillating heart, depolarization wavefronts mo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Systems and methods to assist in locating the focus of an atrial fibrillation include the association of atrial fibrillation cycle length values and statistics relating thereto with temporal locations on an electrogram of a given electrode, and/or the coordination of electrode locations with respective the spectral analyses of electrogram signals and further parameters and statistics relating thereto. Ablation therapy can proceed under guidance of such information.

Description

FIELD OF THE INVENTION [0001] The present invention relates to intervention and treatment of heart conditions such as atrial arrhythmias and more particularly atrial fibrillation with regard to characteristics of the heart tissue itself, and more particularly the present invention concerns the use of atrial fibrillation cycle length determinations in the mapping, diagnosis, treatment and prevention and intervention of atrial fibrillation as well as computer-implemented systems and interfaces relating thereto. BACKGROUND OF THE INVENTION [0002] Atrial fibrillation together with atrial flutter is the most commonly sustained arrhythmia found in clinical practice. Although there has been an increased awareness in the last several years of the potentially serious clinical consequences of both arrhythmias, their basic electrophysiological mechanisms and optimal management strategies only recently have been understood. Atrial fibrillation (AF) involves rapid and chaotic beating of the indi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61B5/296A61B5/361A61B18/14
CPCA61B5/046A61B5/7257A61B18/1492A61B2018/00839A61B2018/00642A61B5/0422A61B18/14A61B2018/00351A61B2018/00577A61B5/04014A61B5/361A61B5/287
Inventor MACADAM, DAVID P.MASHIMO, MINORUFANIER, SYLVAINCOLLINS, TIMHE, DING S.DUBOIS, REMI
Owner BOSTON SCI SCIMED INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products